Bumpus Namandje 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Mar 19, 2025
Insider Transaction Report
Form 4
Bumpus Namandje
Director
Transactions
- Award
Class A Common Stock
2025-03-17+36,549→ 36,549 total - Award
Stock Option (Right to Buy)
2025-03-17+73,099→ 73,099 totalExercise: $6.84Exp: 2035-03-17→ Class A Common Stock (73,099 underlying)
Footnotes (2)
- [F1]Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
- [F2]Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.